Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yuhudie Quban is a proprietary Traditional Chinese Medicine (TCM) capsule developed and manufactured by Hangzhou Qianjin Pharmaceutical. It is specifically indicated for the treatment of melasma (chloasma), particularly cases attributed to liver qi stagnation and blood stasis according to TCM theory. The formulation contains several herbal ingredients, including *Oroxylum indicum* (Yuhudie), *Bupleurum chinense*, *Angelica sinensis*, and *Carthamus tinctorius*. These components work synergistically to regulate endocrine function, improve facial microcirculation, and inhibit the overproduction of melanin. Pharmacologically, active constituents like baicalein found in *Oroxylum indicum* have been shown to inhibit tyrosinase activity, the rate-limiting enzyme in melanin synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yuhudie Quban.